BioProtect

Executive Summary

BioProtect has developed the BioProtect Balloon Spacer, a pre-formed, resorbable balloon implanted to create uniform prostate-rectum separation during radiation therapy for prostate cancer. The device improves dosimetry, reduces rectal toxicity, and preserves patients' bowel, urinary, and sexual quality of life. As a commercial-stage med-tech company based in Israel, BioProtect addresses a significant unmet need in prostate cancer treatment, where radiation-induced rectal toxicity is a common and debilitating side effect. The product is already in use, representing a proven technology with real-world clinical data supporting its efficacy and safety. The company operates in a growing market driven by the increasing incidence of prostate cancer and the adoption of higher-dose radiation regimens. Key growth levers include expanding geographic reimbursement, pursuing regulatory approvals in additional markets (e.g., Asia, Europe), and exploring applications in other radiation-treated cancers. With a strong IP portfolio and a clear clinical value proposition, BioProtect is well-positioned to capture share in the uro-oncology space. This combination of a commercial product, clear clinical benefits, and a large addressable market supports a favorable risk-reward profile for investors.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for expanded indication in other pelvic cancers60% success
• Q3 2026Favorable Medicare reimbursement decision in key EU countries70% success
• Q3 2026Publication of long-term quality-of-life data from pivotal study80% success